Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1819 Phase II Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received the...
Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4375 Clinical Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...
Ouro Medicines Launches with $120M Series A Financing for CM336 Development
Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.’s (HKG: 2162) CM336, has successfully launched...
Menarini Group Expands Oncology Pipeline with Insilico Medicine License
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal...
Zai Lab Secures Rights to Vertex’s Povetacicept in Key Asian Markets
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced an exclusive collaboration and...
Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion
US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm...
Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development
US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the...
Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...
Sepax Technologies Debuts on STAR Market with Soaring IPO Prices
Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on...
Bayer Files for Finerenone Approval in US and China for Heart Failure-Fineline Info & Tech
Bayer AG (ETR: BAYN) has announced market filings with the US Food and Drug Administration...
Pfizer’s Sasanlimab Shows Positive Results in Phase III CREST Study
US-based Pfizer Inc. (NYSE: PFE) has reported positive topline results from its pivotal Phase III...
NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma
China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...
Doma Biopharma Receives FDA Clearance for DM002 Phase I Study-Fineline Info & Tech
China-based Doma Biopharmaceutical (Suzhou) Co., Ltd has announced that it has received clearance from the...
GSK’s Shingrix Prefilled Syringe Accepted for FDA Review
UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has announced that a market filing for a prefilled syringe...
NHSA Launches Nationwide Self-Inspection Campaign on Medical Insurance Fund Usage
China’s National Healthcare Security Administration (NHSA) released a notification last weekend, mandating designated medical institutions...
China’s NHSA Implements New Regulations for Medical Insurance Payment Qualifications
China’s National Healthcare Security Administration (NHSA) has released the “Regulations on the Management of Medical...
Shenzhen Oculgen Secures Over RMB 100 Million in Series A Funding
Shenzhen Oculgen Biomedical Technology Co., Ltd. has successfully completed a Series A financing round, raising...
Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...
Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...